Bernadette Blauensteiner

AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer

Claudia Cardone, Bernadette Blauensteiner, Verónica Moreno‐Viedma et al. · European Journal of Cancer · 2020 · 48 citations

Medicine, Pathology, Colorectal Cancer +7

Gliomasphere marker combinatorics: multidimensional flow cytometry detects <scp>CD</scp>44+/<scp>CD</scp>133+/<scp>ITGA</scp>6+/<scp>CD</scp>36+ signature

Friedrich Erhart, Bernadette Blauensteiner, Gabriel Zirkovits et al. · Journal of Cellular and Molecular Medicine · 2018 · 32 citations · Full text

Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype

Davide Ciardiello, Bernadette Blauensteiner, Nunzia Matrone et al. · Medical Oncology · 2021 · 14 citations · Full text

Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response

Klara Soukup, Angela Halfmann, Barbara Dillinger et al. · Scientific Reports · 2017 · 10 citations · Full text

Spheroid glioblastoma culture conditions as antigen source for dendritic cell-based immunotherapy: spheroid proteins are survival-relevant targets but can impair immunogenic interferon γ production

Friedrich Erhart, Tamara Weiss, Simone Klingenbrunner et al. · Cytotherapy · 2019 · 10 citations

Tumor Immunology, Spheroid Proteins, Cancer Immunosurveillance +14